soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm Editorial Fellow Harleen Marwah, MD, summarizes the trial. Visit NEJM.org for the full results. #ACC25 #Cardiology #ClinicalTrials #MedTok #NEJM Oral Semaglutide Reduces Cardiovascular Events

Name: soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm Editorial Fellow Harleen Marwah, MD, summarizes the trial. Visit NEJM.org for the full results. #ACC25 #Cardiology #ClinicalTrials #MedTok #NEJM Oral Semaglutide Reduces Cardiovascular Events
Brand: matisco.be
SKU: 76561090010
Price: 23.85 USD
Availability: InStock
Rating: 4.0333 (14 reviews)

SKU: 76561090010

4.0

EUR23.85 EUR45.85

Pay in 4 interest-free payments of $5.96 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

Live Spec

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial Oral Semaglutide's Impact on Cardiovascular Events in Type 2 Diabetes Patients with Cardiovascular and Kidney Disease: SOUL Trial Results PPTX Semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss npj Cardiovascular Health Most viewed this week from JAMA: In patients with cardiometabolic #HFpEF, #semaglutide and #tirzepatide reduced the risk of hospitalization for heart failure or all cause mortality vs sitagliptin, but tirzepatide offered no

Store: matisco.be · Domain: matisco.be

Description

No needles, no hasslejust another science-backed tool to bring you exciting results

Causal associations of obesity with chronic kidney disease and arterial stiffness: a mendelian randomization study

Really happy with the progress

For those considering alternatives or wanting to compare their options, resources on phentermine versus semaglutide , Ozempic versus retatrutide , and the broader relationship between GLP-1 and Ozempic can help you understand your options within the GLP-1 medication class